Send me a link:

*Text messaging rates may apply.

 Dow Up0.47% Nasdaq Up0.63%

Endocyte, Inc. (ECYT)

6.34 Up 0.09(1.44%) 4:00PM EDT
|After Hours : 6.24 Down 0.10 (1.58%) 6:37PM EDT
ProfileGet Profile for:
Endocyte, Inc.
3000 Kent Avenue
Suite A1-100
West Lafayette, IN 47906
United States - Map
Phone: 765-463-7175
Fax: 765-463-9271

Index Membership:N/A
Full Time Employees:91

Business Summary 

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Endocyte, Inc.

Corporate Governance 
Endocyte, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 8; Compensation: 4.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. P. Ron Ellis , 52
Co-Founder, Chief Exec. Officer, Pres and Director
Dr. Philip S. Low Ph.D., 66
Co-Founder, Chief Scientific Officer and Director
Mr. Michael A. Sherman , 48
Chief Financial Officer and Chief Operating Officer
Dr. Christopher P. Leamon Ph.D., 48
VP of Research
Mr. Binh Nguyen M.D., Ph.D., 55
VP of Clinical Affairs
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders